Drug Profile
Research programme: neurodegenerative disorder therapies - Mitsubishi Tanabe Pharma/Order made Medical Research/Trans Chromosomics
Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Order-made Medical Research; Trans Chromosomics
- Developer Mitsubishi Tanabe Pharma Corporation; Order-made Medical Research; Trans Chromosomics
- Class Antibodies; Neuroprotectants
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurodegenerative disorders
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for research development in Neurodegenerative-disorders in Japan (Parenteral)
- 13 Dec 2017 Mitsubishi Tanabe Pharma, Order made Medical Research and Trans Chromosomics agree to co-develop antibody therapeutic for neurodegenerative disorders
- 13 Dec 2017 Early research in Neurodegenerative disorders in Japan